Core Viewpoint - Genting New Year (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million, which will result in a 16.1% ownership stake in I-Mab post-transaction [1][2] Group 1 - Genting New Year shares rose over 3% and were trading at HKD 63.5 with a transaction volume of HKD 147 million at the time of reporting [1] - The subscription price of $1.95 per ADS is equivalent to approximately HKD 15.3 per ADS [1] - The total consideration for the subscription amounts to approximately HKD 243 million [1] Group 2 - I-Mab is a global biotechnology company based in the United States, focusing on developing precision immuno-oncology drugs for cancer treatment [1] - I-Mab currently has three clinical-stage pipeline products: Givastomig, Ragistomig, and Uliledlimab [1] - The board believes that the subscription will confirm I-Mab's unique capabilities in clinical translation, particularly in the U.S., and will complement Genting New Year's strong influence in Asia [2]

Core Viewpoint - Clouding New Horizon (01952) has announced a subscription for 15.8462 million American Depositary Shares (ADS) of I-Mab at a price of $1.95 per ADS, totaling approximately $30.9 million, which will result in a 16.1% ownership stake in I-Mab post-transaction [1][2] Group 1 - The subscription price for each ADS is $1.95, equivalent to approximately 15.3 HKD per ADS, with a total transaction value of $30.9 million (approximately 243 million HKD) [1] - After the completion of the subscription, the company will hold a total of 15.8462 million ADS and 6.0786 million ordinary shares of I-Mab, representing about 16.1% of I-Mab's total issued share capital post-transaction [1] - I-Mab is a global biotechnology company focused on developing precision immuno-oncology drugs for cancer treatment, with three clinical-stage pipeline products [1] Group 2 - The board believes that the subscription will confirm I-Mab's unique capabilities in clinical translation, particularly in the U.S., and will complement the company's strong influence in Asia [2] - The collaboration is expected to create synergies between I-Mab's differentiated 4-1BB technology platform and bispecific antibody development pipeline, enhancing the company's existing investments in mRNA cancer vaccines [2]